Total Payments
$14,828
2024 Payments
$1,342
Companies
37
Transactions
288
Medicare Patients
3,483
Medicare Billing
$395,612
Payment Breakdown by Category
Research$10,070 (67.9%)
Food & Beverage$4,629 (31.2%)
Education$99.00 (0.7%)
Other$29.46 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10,070 | 2 | 67.9% |
| Food and Beverage | $4,629 | 284 | 31.2% |
| Education | $99.00 | 1 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $29.46 | 1 | 0.2% |
Payments by Type
Research
$10,070
2 transactions
General
$4,758
286 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $10,070 | 2 | $0 (2021) |
| ABBVIE INC. | $1,152 | 58 | $0 (2024) |
| Janssen Biotech, Inc. | $565.21 | 40 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $515.33 | 30 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $353.23 | 25 | $0 (2024) |
| PFIZER INC. | $312.60 | 20 | $0 (2024) |
| Ardelyx, Inc. | $217.54 | 7 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $196.22 | 5 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $179.36 | 26 | $0 (2018) |
| Shire North American Group Inc | $141.74 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,342 | 73 | ABBVIE INC. ($368.30) |
| 2023 | $1,169 | 46 | AbbVie Inc. ($464.79) |
| 2022 | $58.72 | 1 | Promega Corporation ($58.72) |
| 2021 | $10,070 | 2 | Eli Lilly and Company ($10,070) |
| 2020 | $111.70 | 2 | Janssen Biotech, Inc. ($99.00) |
| 2018 | $1,088 | 102 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($184.75) |
| 2017 | $988.51 | 62 | AbbVie, Inc. ($152.89) |
All Payment Transactions
288 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: GI | ||||||
| 11/12/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/05/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 10/22/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/16/2024 | Sandoz Inc. | — | Food and Beverage | In-kind items and services | $19.28 | General |
| 10/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/15/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/15/2024 | Medtronic, Inc. | INTERSTIM (Device) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Sacral Nerve Stimulation | ||||||
| 10/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: IMMUNOLOGY | ||||||
| 10/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Immunology | ||||||
| 10/08/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | Mauna Kea Technologies, Inc. | — | Food and Beverage | Cash or cash equivalent | $17.31 | General |
| 09/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2024 | Mauna Kea Technologies, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.39 | General |
| 09/10/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $10,000 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $70.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 933 | 1,045 | $416,490 | $104,653 |
| 2022 | 15 | 842 | 907 | $365,837 | $92,262 |
| 2021 | 15 | 936 | 1,042 | $408,014 | $109,377 |
| 2020 | 13 | 772 | 868 | $310,786 | $89,320 |
Total Patients
3,483
Total Services
3,862
Medicare Billing
$395,612
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 217 | 219 | $144,633 | $27,917 | 19.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 90 | 90 | $63,846 | $19,471 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 149 | 218 | $30,956 | $13,038 | 42.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 161 | 171 | $77,292 | $11,632 | 15.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 44 | 44 | $21,692 | $8,216 | 37.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 69 | $13,869 | $5,559 | 40.1% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 35 | 36 | $15,768 | $3,918 | 24.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 17 | 17 | $8,398 | $3,220 | 38.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $6,550 | $3,161 | 48.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $6,475 | $2,575 | 39.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 33 | 38 | $4,408 | $1,894 | 43.0% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Office | 2023 | 21 | 34 | $8,024 | $1,195 | 14.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $2,321 | $1,166 | 50.2% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $3,575 | $803.18 | 22.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 11 | $1,221 | $705.87 | 57.8% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $7,462 | $180.88 | 2.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 202 | 203 | $129,717 | $24,705 | 19.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 93 | 94 | $65,706 | $19,732 | 30.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 141 | 145 | $65,540 | $9,735 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 131 | $18,602 | $8,036 | 43.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 39 | 39 | $19,245 | $7,457 | 38.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 59 | $11,859 | $5,011 | 42.3% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 30 | 30 | $13,140 | $3,147 | 23.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 40 | 40 | $7,000 | $3,080 | 44.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 20 | $4,220 | $2,226 | 52.7% |
About Dr. John Weber, MD
Dr. John Weber, MD is a Gastroenterology healthcare provider based in Troy, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1770568289.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Weber, MD has received a total of $14,828 in payments from pharmaceutical and medical device companies, with $1,342 received in 2024. These payments were reported across 288 transactions from 37 companies. The most common payment nature is "" ($10,070).
As a Medicare-enrolled provider, Weber has provided services to 3,483 Medicare beneficiaries, totaling 3,862 services with total Medicare billing of $395,612. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Troy, MI
- Active Since 12/08/2005
- Last Updated 02/12/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1770568289
Products in Payments
- STELARA (Biological) $565.21
- RINVOQ (Biological) $372.43
- SKYRIZI (Biological) $359.46
- XIFAXAN (Drug) $302.73
- XELJANZ (Drug) $225.00
- IBSRELA (Drug) $217.54
- Entyvio (Biological) $204.70
- DUPIXENT (Biological) $199.52
- ENTYVIO (Biological) $183.11
- Trulance (Drug) $179.36
- GATTEX (Drug) $141.74
- OCA (Drug) $116.90
- Viekira (Drug) $113.53
- LINZESS (Drug) $104.58
- Mavyret (Drug) $85.94
- TRULANCE (Drug) $81.42
- OCALIVA (Drug) $79.32
- MOVIPREP (Drug) $71.61
- Humira (Biological) $70.74
- Dexilant (Drug) $68.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Troy
Dr. Partha Nandi, Md, MD
Gastroenterology — Payments: $242,021
Gastroenterology $242,021
Dr. Barry Pronold, M.d, M.D
Gastroenterology — Payments: $17,199
Gastroenterology $17,199
Dr. Mehmet Donat, Md, MD
Gastroenterology — Payments: $8,874
Gastroenterology $8,874
Dr. Robert Lamport, Md, MD
Gastroenterology — Payments: $7,628
Gastroenterology $7,628
Dr. Richard Wille, Md, MD
Gastroenterology — Payments: $4,855
Gastroenterology $4,855
Dr. Sante Bologna, Md, MD
Gastroenterology — Payments: $3,761
Gastroenterology $3,761